Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13650086 | 0.84 | MEN1 (0.45) | PPARGALDH1A1MAPTKDM4EHTT | |
| SCHEMBL13650099 | 0.81 | MEN1 (0.44) | ALDH1A1MAPTKDM4EHTTMEN1 | |
| SCHEMBL13650085 | 0.80 | CFTR (0.56) | MEN1KMT2ASIRT1 | |
| SCHEMBL13650098 | 0.78 | CFTR (0.53) | MEN1KMT2ASIRT1 | |
| SCHEMBL13650082 | 0.77 | SIRT1 (0.50) | PPARGALDH1A1MAPTKDM4EHTT | |
| SCHEMBL13650100 | 0.76 | KMT2A (0.44) | PPARGALDH1A1MAPTKDM4EHTT | |
| SCHEMBL13650102 | 0.73 | MAPT (0.54) | PPARGALDH1A1MAPTKDM4EMEN1 | |
| SCHEMBL13650101 | 0.73 | HIF1A (0.49) | ALDH1A1MAPTKDM4EHTTMEN1 | |
| SCHEMBL12648739 | 0.72 | CFTR (0.60) | ALDH1A1MAPTKDM4EMEN1KMT2A | |
| SCHEMBL13650087 | 0.72 | SIRT1 (0.37) | ALDH1A1MAPTKDM4EHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253799-A1 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SLC26A4, SLC26A3 | PPARG 2874/4885ALDH1A1 3503/4885MAPT 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.